RAB6A

Across TCGA pan-cancer cohorts, RAB6A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RAB6A data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RAB6A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAB6A expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where RAB6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	34	view →
HNSC	OS	Quartile	II,III,IV	0.879	0.580	.020	12	view →
PDAC	OS	Median	IV	0.491	0.836	.024	6	view →
UCEC	DFS	Quartile	All	0.833	1.000	.026	4	view →
LSCC	DFS	Quartile	II,III,IV	0.187	0.766	.024	4	view →
LUAD	OS	Tertile	II,III,IV	0.694	0.975	.027	3	view →
GBM	OS	Tertile	All	0.869	0.729	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RAB6A–CCRCC (DFS)

Open the CCRCC breakdown →